Skip to main content

uniQure N.V.

corporate_fare Company Profile

uniQure N.V.

QURE·NASDAQ·Life Sciences·CIK 0001590560

uniQure N.V. is a gene therapy company focused on developing single treatments for rare and other devastating diseases with potentially curative results. The company is advancing a pipeline of gene therapies, including clinical candidates for Huntington's disease, refractory mesial temporal lobe epilepsy (MTLE), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (SOD1-ALS). In September 2025, uniQure N.V. announced positive topline data from the pivotal Phase I/II study of AMT-130 for Huntington's disease. The study analyzed clinical outcomes for 29 patients treated with AMT-130 (17 high-dose; 12 low-dose). At the 36-month follow-up, 12 patients per dose group were evaluated. Outcomes for each dose group were compared to a propensity score-matched external control from the Enroll-HD natural history data set (940 for high-dose; 626 for low-dose). As of June 30, 2025, 36-month efficacy results for high-dose AMT-130 showed a statistically significant 75% slowing of disease progression as measured by composite Unified Huntington's Disease Rating Scale (cUHDRS) (p=0.003), meeting the primary endpoint. Treated patients had a mean change in cUHDRS from baseline of -0.38, compared to -1.52 for the external control. Additionally, there was a statistically significant 60% slowing of disease progression as measured by Total Function Capacity (TFC) (p=0.033), meeting a key secondary endpoint. Treated patients had a mean change in TFC from baseline of -0.36, compared to -0.88 for the external control. Favorable trends were also observed in other secondary endpoint measures of motor and cognitive function, including Symbol Digit Modalities Test (SDMT), Stroop Word Reading Test (SWRT), and Total Motor Score (TMS).

uniQure N.V. (NASDAQ:QURE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for QURE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • FDA Accepts Phase 1/2 Data for uniQure's AMT-130 BLA, Plans Q3 Submission
  • Shareholders Approve Major Increase in Authorized Shares and Incentive Plan, Boosting Potential Dilution
  • uniQure Reports Increased Loss, Pursues UK Regulatory Path for AMT-130 Amidst Clinical Setbacks
  • uniQure's Lead HD Program AMT-130 Faces FDA Setback, ALS Program Discontinued Amid Q1 Loss; Strong Cash Runway Maintained
  • 75% Disease Slowing: uniQure's AMT-130 Nears UK Submission for Huntington's

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$16.1M
Net Income
-$198.97M
Diluted EPS
-$3.46
Op. Cash Flow
-$177.96M
Free Cash Flow
-$178.4M
Gross Profit
$14.41M
Operating Income
-$185.35M
Cash & Equivalents
$80.24M
Total Debt
$49.7M
Debt / Equity
0.25×
Net Margin
-12.36×
Shares Outstanding
62.34M sh
Source: 10-K · filed 2026-03-02 · accession 0001104659-26-021898
$20.12 +3.98% today
52-week range · as of 2026-11-04 $8.73 – $51.72
Market cap
$1.36B
Volume
2.1M (1.1× avg)
3-mo avg 1.9M
Live data · 2026-11-21 21:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed QURE - Filings & News (Page 2)

QURE
Jun 17, 2026, 7:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.50
Real-time Price: $20.12 info
Change: -$7.38 (-27%) info
Market Cap: $1.357B info
QURE
Jun 15, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $27.87
Real-time Price: $20.12 info
Change: -$7.75 (-28%) info
Market Cap: $1.357B info
QURE
May 05, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.89
Real-time Price: $20.12 info
Change: -$0.770 (-4%) info
Market Cap: $1.357B info
QURE
May 05, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.89
Real-time Price: $20.12 info
Change: -$0.770 (-4%) info
Market Cap: $1.357B info
QURE
Apr 30, 2026, 7:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $17.75
Real-time Price: $20.12 info
Change: +$2.37 (+13%) info
Market Cap: $1.357B info
QURE
Apr 27, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $18.53
Real-time Price: $20.12 info
Change: +$1.59 (+9%) info
Market Cap: $1.357B info
QURE
Apr 16, 2026, 5:00 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $16.82
Real-time Price: $20.12 info
Change: +$3.30 (+20%) info
Market Cap: $1.357B info
QURE
Mar 23, 2026, 9:40 PM EDT
Source: Access Newswire
Importance Score:
8
Price at Filing: $15.62
Real-time Price: $20.12 info
Change: +$4.50 (+29%) info
Market Cap: $1.357B info
QURE
Mar 03, 2026, 5:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $10.12
Real-time Price: $20.12 info
Change: +$10.00 (+99%) info
Market Cap: $1.357B info
QURE
Mar 02, 2026, 7:24 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $8.65
Real-time Price: $20.12 info
Change: +$11.47 (+133%) info
Market Cap: $1.357B info
QURE
Mar 02, 2026, 7:09 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $9.20
Real-time Price: $20.12 info
Change: +$10.92 (+119%) info
Market Cap: $1.357B info
QURE
Mar 02, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.99
Real-time Price: $20.12 info
Change: +$11.13 (+124%) info
Market Cap: $1.357B info
QURE
Feb 26, 2026, 9:20 PM EST
Source: Acceswire
Importance Score:
7
Price at Filing: $16.82
Real-time Price: $20.12 info
Change: +$3.30 (+20%) info
Market Cap: $1.357B info
QURE
Jan 13, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.54
Real-time Price: $20.12 info
Change: -$1.42 (-7%) info
Market Cap: $1.357B info
QURE
Jan 09, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.49
Real-time Price: $20.12 info
Change: -$4.37 (-18%) info
Market Cap: $1.357B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets